PMID- 18220322
OWN - NLM
STAT- MEDLINE
DCOM- 20080729
LR  - 20181201
IS  - 0278-0232 (Print)
IS  - 0278-0232 (Linking)
VI  - 26
IP  - 2
DP  - 2008 Jun
TI  - ALK-positive diffuse large B-cell lymphoma: report of three cases.
PG  - 108-13
LID - 10.1002/hon.841 [doi]
AB  - Diffuse large B-cell lymphoma positive for anaplastic lymphoma kinase (ALK(+) 
      DLBCL) is a rare variant of diffuse large B-cell lymphoma, with characteristic 
      morphological, immunohistochemical and cytogenetic features. Only 34 cases of 
      ALK-positive diffuse large B-cell lymphoma have so far been reported in the 
      literature. We examined three new cases, which showed similar characteristics to 
      previously reported cases, but with peculiar nuclear-membrane staining for ALK 
      protein in one patient and a 5'-ALK gene deletion in another. All of them had 
      stage IV disease at initial presentation, with poor outcomes. The tumour cells 
      showed immunoblastic/plasmablastic histology and were positive for ALK and Oct2, 
      but negative for CD3, CD20, CD79a, CD30 and PAX5. The staining pattern of ALK 
      protein was cytoplasmic in two patients and associated with the nuclear membrane 
      in one patient. Fluorescence in situ hybridization (FISH) analysis using the ALK 
      break-apart probe revealed ALK gene rearrangements in all three patients, with a 
      5'-ALK gene deletion in one patient. These three cases suggest that different 
      types of cytogenetic aberrations may involve the ALK gene in ALK-positive diffuse 
      large B-cell lymphoma leading to peculiar immunohistochemical staining patterns.
FAU - Lee, Hyoun Wook
AU  - Lee HW
AD  - Department of Pathology, Dong-A University, Pusan, Korea.
FAU - Kim, Kihyun
AU  - Kim K
FAU - Kim, Wonseog
AU  - Kim W
FAU - Ko, Young Hyeh
AU  - Ko YH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Anaplastic Lymphoma Kinase
MH  - Cell Nucleus/metabolism
MH  - Chromosome Aberrations
MH  - Cytogenetics
MH  - Female
MH  - Gene Deletion
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/*diagnosis/*therapy
MH  - Male
MH  - Protein-Tyrosine Kinases/*biosynthesis/*genetics
MH  - Receptor Protein-Tyrosine Kinases
MH  - Treatment Outcome
EDAT- 2008/01/29 09:00
MHDA- 2008/07/30 09:00
CRDT- 2008/01/29 09:00
PHST- 2008/01/29 09:00 [pubmed]
PHST- 2008/07/30 09:00 [medline]
PHST- 2008/01/29 09:00 [entrez]
AID - 10.1002/hon.841 [doi]
PST - ppublish
SO  - Hematol Oncol. 2008 Jun;26(2):108-13. doi: 10.1002/hon.841.